RxDoctor Payments Data

Iulia Platte, MD

Internal Medicine · St. Augustine, FLNPI 1437359981

Payments from drug & device makers

$8,775in general payments, 2019–2025

Across 510 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$820
  • Boehringer Ingelheim$762
  • Lilly USA, LLC$743
  • AbbVie$742
  • Pfizer$720
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,775100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,775 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$127,652
Medicare patients
349
Services billed
1,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide113$130,663
EliquisApixaban54$44,389
JardianceEmpagliflozin47$42,569
MounjaroTirzepatide33$36,337
LinzessLinaclotide17$21,326
TrulicityDulaglutide18$18,414
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,584
Breo ElliptaFluticasone/Vilanterol21$10,769
SynthroidLevothyroxine Sodium53$5,282
NexletolBempedoic Acid12$4,817
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,928
Rosuvastatin Calcium304$3,792
Alendronate Sodium131$3,737
Wixela InhubFluticasone Propion/Salmeterol28$3,693
Levothyroxine Sodium315$3,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,120$130,663113 claims
Lilly USA, LLCMounjaro, Trulicity$743$54,75151 claims
PfizerEliquis$720$44,38954 claims
Boehringer IngelheimJardiance$762$42,56947 claims
GSKTrelegy Ellipta, Breo Ellipta$548$28,35349 claims
AbbVieLinzess, Synthroid$742$26,60770 claims
Esperion Therapeutics, Inc.Nexletol$77$4,81712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in St. Augustine

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →